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Abstract  Standardized  terminology  developed  by  the  American  College  of  Radiography  (ACR)
through the  Breast-Imaging  Reporting  and  Data  System  (BI-RADS)  lexicon  is  used  worldwide  to
describe the  ﬁndings  of  the  various  breast-imaging  techniques  (mammography,  ultrasound,  and
magnetic  resonance  imaging  (MRI)).  A  7-level  positive  predictive  value  (PPV)  of  malignancy  clas-
siﬁcation system  (from  BI-RADS  category  0  to  category  6)  has  been  based  on  this  terminology,
giving imaging  a  central  role  in  the  diagnostic  strategy.  This  document  presents  the  standard-
ized, compulsory  BI-RADS  terminology  used  in  breast-imaging  reports  in  2013  in  view  of  the  new
edition that  will  be  published  at  the  end  of  the  year.
© 2014  Éditions  franc¸aises  de  radiologie.  Published  by  Elsevier  Masson  SAS.  All  rights  reserved.
Mammography
Mammography  is  the  gold  standard  screening  examination,  and  the  ﬁrst  diagnostic
examination  in  a  breast-imaging  work-up.  Standard  mammography  comprises  bilateral
craniocaudal  and  45◦ mediolateral  oblique  views.  The  breast-imaging  report  includes:
Clinical contextThe  following  clinical  information  must  be  included:  patient’s  age,  hormonal  status  (pre-
or  post-menopausal,  hormone  replacement  therapy),  personal  and  family  history  of  breast
and  ovarian  disease,  and  previous  surgical  history.
∗ Corresponding author. Service de radiologie, 4, rue de la Chine, 75020 Paris, France.
E-mail address: isabellethomassin@gmail.com (I. Thomassin-Naggara).
http://dx.doi.org/10.1016/j.diii.2014.06.006
2211-5684/© 2014 Éditions franc¸aises de radiologie. Published by Elsevier Masson SAS. All rights reserved.
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trauma  or  surgery,  usually  related  to  a  cytosteatonecrosis.60  
The  result  of  the  clinical  examination  should  appear  in
his  paragraph  and  the  availability  of  previous  mammogra-
hies  for  comparison  (specifying  the  dates).
echnique
he  type  of  mammograph  used  to  perform  the  examination
hould  be  recorded  and  the  date  in  which  it  was  brought
nto  service.  It  is  also  important  to  record  the  mean  glan-
ular  dose  (MGD)  and  the  number  of  exposures/breast,
specially  if  the  MGD  values  do  not  appear  on  the  ﬁlms
in  this  situation,  enter  the  value  of  the  MGD  obtained  at
he  last  six-monthly  quality  control).  If  a  technical  problem
s  encountered,  for  example  a  particular  morphology  that
imits  correct  positioning,  it  is  also  advisable  to  record  it
ere.
esults
reast  composition
he  composition  of  the  breast  is  scored  from  1  to  4  as  a
unction  of  the  percentage  of  breast  glandular  tissue  in  the
reast.
type  1:  the  breast  is  almost  entirely  fatty;
type  2:  there  are  scattered  areas  of  ﬁbroglandular  den-
sity;
type  3:  the  breasts  are  heterogeneously  dense,  which  may
obscure  small  masses;
type  4:  the  breasts  are  extremely  dense  (homogeneously
dense).
escription  of  the  main  anomalies
our  semiological  entities  are  described  in  the  BI-RADS  ter-
inology:  masses,  asymmetries,  architectural  distortion,
nd  calciﬁcations.  The  anatomical  location  (quadrant,  dis-
ance  from  the  nipple,  and  depth)  and  size  must  be  reported
or  each  entity  described.  It  is  also  essential,  where  previ-
us  mammograms  are  available,  to  assess  the  development
onset,  progression,  stability,  modiﬁcation,  or  regression).
ass
 mass  is  deﬁned  as  a  space-occupying  lesion  that  is  visible
n  two  different  views.  If  a  potential  mass  is  only  seen  on
ne  view,  it  should  be  reported  as  an  ‘‘asymmetry’’  until  its
hree-dimensional  character  is  conﬁrmed.
Masses  are  characterized  according  to  three  criteria:
hape,  margin,  and  density.  Therefore,  spot  compression
iews  are  essential  to  better  assess  the  margin  of  masses
ecause  this  criterion  has  the  greatest  positive  predictive
alue  for  malignancy.  When  the  mass  is  located  in  fatty  tis-
ue,  or  if  there  is  a  doubt  over  the  presence  of  associated
alciﬁcations,  magniﬁcation  views  are  useful  (increase  in
patial  resolution).  An  additional  mediolateral  view  can  help
o  deﬁne  the  exact  localisation  of  the  anomaly.
The  descriptive  criteria  that  should  be  used  to  describe
 mass  are  presented  in  decreasing  order  of  PPV  for  malig-
ancy.
shape:  oval  (including  macrolobulations),  round,
microlobular,  and  irregular;
margin:  circumscribed  or  non-circumscribed  (indistinct,
obscured,  or  spiculated);
c
bI.  Thomassin-Naggara  et  al.
density:  deﬁned  in  comparison  with  the  gland,  the  lesion
can  be  described  as  hypodense,  isodense,  or  hyper-
dense.  Classically,  malignant  lesions  are  hyperdense  in
comparison  with  the  gland,  but  this  sign  has  a  low  PPV
for  malignancy.
Fatty  or  completely  calciﬁed  masses  are  classiﬁed  as
CR2  (benign).  Other  masses  should  be  examined  with  ultra-
ound  to  determine  their  ﬁnal  BI-RADS  classiﬁcation.
symmetries
hese  densities  have  a  similar  shape  on  both  views,  but
ithout  the  margin  and  sharpness  of  a  true  mass.  Their
‘asymmetrical’’  nature  implies  that  the  ﬁlms  have  been
ead  side  by  side  as  mirror  images,  revealing  differences
etween  the  right  and  left  sides.  Three  elements  should  be
ssessed  to  conﬁrm  the  presence  of  a  true  asymmetry:  is
t  a  projection  of  a lesion  that  is  outside  the  breast?  Is  it
 superimposition  image?  Is  the  other  view  technically  cor-
ect?  Mediolateral  and  spot  compression  views  are  therefore
equired.
Correlation  with  the  clinical  examination  is  crucial
nd  mainly  the  palpable  character  of  the  abnormality.  In
ecreasing  order  of  importance,  the  imaging  features  are  as
ollows:  development,  presence  of  associated  signs  (calci-
cations,  architectural  distortion),  analysis  of  the  margin,
ype  of  asymmetry,  and  the  presence  of  a  density  gradient.
The  descriptive  criteria  for  asymmetries  are  as  follows:
development:  new,  developing,  or  stable;
associated  features:  architectural  distortion  or  calciﬁca-
tions;
margin:  a  convex  margin  has  a  poorer  prognosis  than  a
concave  one  described,  often  as  ‘‘geographical’’;
type:  global  (>  1  quadrant),  focal  (<  1  quadrant);
density  gradient:  the  presence  of  a  fatty  component  is  a
reassuring  element.
In  summary,  any  asymmetry  must  be  examined  with
ltrasound,  and  the  BI-RADS  category  revised  if  positive.
symmetries  present  an  overall  risk  of  malignancy  of  1.8%.
n  the  case  of  associated  distortion,  the  abnormality  is  clas-
iﬁed  as  BI-RADS  category  5.  A  developing  asymmetry  has  a
PV  for  malignancy  of  13-27%  and  is  therefore  given  an  ACR
core  of  4a  or  4b  depending  on  the  analysis  of  the  margin.  In
he  absence  of  ultrasound  abnormality,  a  focal  asymmetry
ithout  any  other  negative  criteria  is  classiﬁed  as  BI-RADS
ategory  3.  An  overall  non-palpable  asymmetry  has  a  PPV
or  malignancy  of  0%  and  is  given  a  BI-RADS  category  2  in
he  absence  of  associated  ﬁndings.  In  the  event  of  a  palpa-
le  mass,  the  PPV  for  malignancy  is  15%  and  the  anomaly  is
lassed  as  BI-RADS  category  4b.
rchitectural  distortion
 proven  distortion  is  visible  on  two  views.  If  this  distor-
ion  is  only  visible  on  one  view,  the  ﬁrst  step  is  to  rule  out
 superimposition  image  and  the  second  step  is  to  analyze
he  clinical  context  to  rule  out  scarring  linked  to  a  previousIt  is  important  to  conﬁrm  the  distortion  with  a  spot
ompression  view.  Breast  tomosynthesis  will  certainly
ecome  more  important  in  the  future  for  the  deconstruction
Standardized  diagnosis  and  reporting  of  breast  cancer  761
Table  1  Summary  of  the  analysis  of  microcalciﬁcations.
Distribution  morphology  Diffuse  and  bilateral  Focal  or  regional  apparent  Ductal,  segmental  or
with  K  associated
Round  or  punctiform  ACR  2  ACR  3  ACR  4A
Coarse  or  heterogeneous  ACR  4A  ACR  4  C
Amorphous  ACR  2  ACR  4A  ACR  4  C
Fine  and  polymorphous ACR  4A  ACR  4B  ACR  4  C
Line,  linear,  or  branching ACR  4  C ACR  5
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cof  superposition  images,  which  are  a  source  of  false  posi-
tives.
Distortions  with  a  denser  center  have  a  poorer  prognosis
than  those  with  a  radiolucent  centre.  The  size  and  shape  of
spicules  should  be  described:  suspicious  spicules  are  thick
and  short,  compared  to  long  and  thin  spicules.
Any  proven  architectural  distortion  is  classiﬁed  as  at  least
BI-RADS  category  4.
Clusters  of  calciﬁcations
• this  is  deﬁned  as  the  presence  of  at  least  ﬁve  calciﬁcations
measuring  less  than  1  mm  over  an  area  of  less  than  1  cm2.
It  is  important  to  check  that  they  are  indeed  microcalciﬁ-
cations  and  not  macrocalciﬁcations  (vascular,  scar  tissue,
parietal,  benign  galactophoric,  or  sedimentary)  [1];
• it  is  a  focal  lesion  and  not  scattered  calciﬁcations;
• the  cluster  is  indeed  intramammary  (veriﬁcation  by  tri-
angulation  —  take  a  lateral  view  then  align  according  to
AP  —  Oblique  —  Lateral).
Firstly,  check  whether  the  cluster  of  calciﬁcations  is
associated  with  a  mass,  an  asymmetrical  density,  or  an  archi-
tectural  distortion,  which  will  have  a  major  impact  on  the
BI-RADS  classiﬁcation  of  the  cluster  of  calciﬁcations.  Next,
by  order  of  importance,  analyze  the  spatial  distribution  of
the  calciﬁcations.  Thirdly,  determine  the  morphology  and
density  of  the  calciﬁcations.  Fourthly,  determine  the  homo-
geneity  of  the  shape  and  density  of  the  calciﬁcations.  Fifthly,
count  the  number  of  calciﬁcations,  and  lastly,  establish  their
progression  over  time  (comparison  with  previous  mammo-
grams  if  available)  [2—4].
Distribution  of  microcalciﬁcations:  segmental,  linear,
grouped,  regional,  and  diffuse  or  scattered  (decreasing
order  of  PPV  for  malignancy).
Morphology  and  density:
• high  risk  of  malignancy  (ﬁne  pleomorphic,  and/or
ﬁne  linear  branching  calciﬁcations),  intermediate  risk
of  malignancy  (large  and  heterogeneous  calciﬁcations,
amorphous  or  scattered  calciﬁcations),  low  risk  of  malig-
nancy  (amorphous  calciﬁcations  in  round  clumps);
• homogeneity  of  calciﬁcations:  analysis  of  the  pleomorphic
character  of  the  calciﬁcations  (negative  value  if  present);
• number  of  calciﬁcations:  if  the  morphology  is  reassur-
ing,  the  presence  of  more  than  10  calciﬁcations/cm2 is
a  negative  criterion;• development  over  time:  similarly,  this  criterion  is  only
considered  if  the  morphology  is  reassuring  and  is  negative
if  developing.  Ideally,  this  analysis  should  be  performed
with  a  minimum  of  two  years  follow-up.
m
b
sTable  1  summarizes  the  classiﬁcation  of  calciﬁcations  as
 function  of  the  two  main  criteria:  their  distribution  and
orphology.  The  benign  categories  should  be  considered  in
ight  of  the  number  of  calciﬁcations  and  their  development
ver  time  [5—7].
reast ultrasound
linical context
he  indications  for  breast  ultrasound  include:  the  presence
f  a  clinical  abnormality,  an  abnormal  mammography,  type
 and  4  breast  densities  and  certain  breasts  with  a  type  2
ensity  with  a  retro-areolar  glandular  area.  The  indication
or  ultrasound  examination  can  be  speciﬁed  at  the  beginning
f  the  paragraph.
echnique
he  type  of  machine  used  should  be  recorded  in  the  report
with  the  publication  of  the  new  BI-RADS  terminology,  the
se  of  elastography  should  probably  be  mentioned).  Accord-
ng  to  the  recommendations  of  the  French  National  Cancer
nstitute  (INCa)  (2012),  all  breast  ultrasound  examinations
or  breast  cancer  (BI-RADS  category  5  or  6)  should  include
n  exploration  of  the  axilla  during  the  same  session.
esults
issue  composition
he  homogeneity  and  composition  of  the  tissue  should  be
ssessed  as  this  will  affect  the  diagnostic  performance  of  the
xamination.  The  breast  may  be  homogeneous  and  purely
atty,  composed  of  homogeneous  hypoechoic  lobules,  sepa-
ated  by  Cooper’s  ligaments,  or  homogeneous  and  glandular
ith  a  thin  layer  of  subcutaneous  fat.  The  breast  can  also
e  heterogeneous  with  multiple  hypoechoic  zones,  which
akes  the  detection  of  hypoechoic  nodules  more  difﬁcult.
escription  of  abnormalities
asses
hen  a  nodule  is  detected  in  one  axis,  it  is  important  to
onﬁrm  its  presence  along  a  perpendicular  axis.  Further-
ore,  the  morphological  analysis  and  measurement  should
e  performed  in  two  perpendicular  planes.
The  analysis  should  give  a  detailed  description  of  the
hape,  margin,  orientation  with  respect  to  the  skin,  the
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chostructure  with  respect  to  the  subcutaneous  fat,  and
osterior  features  (enhancement,  posterior  attenuation).
The  descriptive  criteria  are  as  follows:
shape:  by  decreasing  order  of  PPV  for  malignancy:
irregular,  round,  oval;
orientation:  perpendicular  to  the  skin  interrupting  the
normal  architecture  of  the  gland  is  predictive  of  malig-
nancy;
margin:  circumscribed  (usually  benign),  or  not  circum-
scribed  (such  as  hyperechoic  halo,  indistinct,  angular,
spiculated,  and  microlobulated);
echo  pattern:  anechoic,  hyperechoic  (usually  benign),  or
hypoechoic;
posterior  attenuation  of  the  ultrasound  beam:  negative
sign  if  present;
elasticity:  hard  lesions  present  a  higher  PPV  for  malig-
nancy.  The  descriptive  criteria  are  deﬁned  in  the  new
BI-RADS  terminology.
ltrasonographic  non-mass
alciﬁcations  can  be  seen  and  should  therefore  be
escribed.  This  group  also  includes  echoic  galactophoric
ctasias,  or  hyperechoic  zones  of  echostructural  alteration
ith  no  individually  distinct  nodules.
urrounding  tissues
xamination  of  the  surrounding  tissue  should  include  a
escription  of  any  echostructural  distortions,  duct  ectasia,
kin  retraction,  edema,  and/or  hypervascularization,  which
re  all  negative  elements.
pecial  cases
ypical  ultrasound  images  that  should  be  recognized  and
ccurately  described  include:
intramammary  lymph  nodes:  hypoechoic  circumscribed
small  oval  or  reniform  mass  with  echogenic  hilum;
clustered  microcysts:  cluster  of  tiny  anechoic  foci,
1—7  mm  with  thin  intervening  septae  without  any  solid
component  (usually  located  in  the  superolateral  quad-
rant);
intra-galactophoric  mass:  echoic  nodule  located  in  a  duct
ectasia;  Doppler  analysis  is  useful  for  assessing  the  pres-
ence  of  Doppler;
cutaneous  or  dermal  mass:  space-occupying  nodule  in  the
subcutaneous  tissue;
treated  breast:  echostructural  disorganization  with  a
post-surgical  scar.  Check  that  this  scar  remains  thin  and
regular  by  exerting  moderate  pressure  on  the  probe  to
spread  the  tissues.ummary
he  following  are  classiﬁed  as  ACR  2:  anechoic  lesions
cysts),  intramammary  lymph  nodes,  cutaneous  or  dermal
asses,  and  hyperechoic  nodules  without  negative  signs.
The  following  are  classiﬁed  as  ACR  3:  hypoechoic  nodules,
ith  the  largest  axis  in  the  horizontal  plane,  homogeneous,
val,  with  regular  margins,  without  posterior  shadowing,
nd  clustered  of  microcysts.
P
•
•
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The  following  are  classiﬁed  as  ACR  4  or  5:  all  other
asses.
reast MRI
reast  MRI  is  a  second-line  technique  performed  in  combi-
ation  with  mammography  and  breast  ultrasonography.  The
ndications  for  breast  MRI  are  multiple  and  include  screening
f  women  with  a  high  risk  of  breast  and  ovarian  cancer
nd  the  locoregional  extension  proﬁle  of  breast  cancer  in
ertain  speciﬁc  situations  (under  40  years  old,  neoadju-
ant  chemotherapy,  radio-clinical  discordance,  oncoplastic
ecision-making,  invasive  lobular  cancer).  The  breast  MRI
eport  should  include  the  clinical  context,  technique,  and
esults.
linical context
his  should  include  the  following  information,  which  is
ssential  for  interpretation:  patient’s  age,  menopausal  sta-
us  (hormone  replacement  therapy  or  not),  period  of  the
enstrual  cycle,  previous  personal  history  of  breast  or  ovar-
an  pathology,  surgical  history  (specify  the  site  of  the  scar),
revious  family  history  of  breast  or  ovarian  cancer.  Data
rom  conventional  mammography  and  ultrasound  imaging,
nd  the  results  of  any  previous  breast  MRIs  are  essential.
echnique
t  is  important  to  specify  in  this  paragraph,  which  sequences
ere  acquired  and  what  post-treatments  were  performed
Appendix  A).
esults
ackground  parenchymal  enhancement  should  be  scored
rom  1  to  4  to  give  the  clinician  a  notion  of  quality  of  inter-
retation.  For  each  abnormality  detected,  it  is  important
o  specify  the  exact  location:  laterality,  quadrant  and  clock
ace,  distance  from  the  nipple.  It  is  very  useful  to  indicate
he  number  of  the  slice  on  which  the  lesion  was  detected,
otably  with  a  view  to  a  second  intention  targeted  ultra-
ound  examination.
There  are  three  types  of  breast  MRI  uptake  anomalies:
asses,  non-mass  enhancement,  and  focus.
ass
his  is  a  space-occupying  volume  (convex  contours  in  the
hree  spatial  planes).
A  mass  is  characterized  according  to  its  shape,  margin,
nternal  enhancement  characteristics,  and  its  kinetic  curve
ssessment.
The  descriptive  criteria  of  a  mass,  in  increasing  order  of
PV  for  malignancy  are  as  follows:
shape:  round,  oval,  lobular,  or  irregular;
margins:  smooth,  irregular,  spiculated;
internal  enhancement  patterns:  homogeneous,  hetero-
geneous,  annular,  central.  The  existence  of  internal
septations  that  are  not  enhanced  after  injection  should
also  be  described  as  these  are  indicative  of  a  benign  mass;
Standardized  diagnosis  and  reporting  of  breast  cancer  763
Figure 1. Report of a mammary MRI [8] in a patient with a low risk of breast cancer.
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h• kinetic  enhancement  curve:  there  are  three  types  of
curve:  type  1  (slow  and  progressive),  type  2  (medium
with  a  plateau),  and  type  3  (fast,  early  with  secondary
washout).  The  analysis  of  these  curves  provides  useful
information  in  cases  with  a  benign  morphology.
The  combination  of  the  various  criteria  and  the  resulting
classiﬁcation  in  patients  who  do  not  have  a  high  risk  of  breast
cancer  is  presented  in  Fig.  1  [8].
Non-mass  enhancement
Non-mass  enhancement  (NME)  is  the  enhancement  of  a zone
that  is  not  a  mass  or  a  vascular  structure,  and  which  meas-
ures  more  than  5  mm.  By  deﬁnition,  it  is  a  process  that  is  not
space-occupying  and  which  cannot  be  seen  on  non-enhanced
sequences.
Non-mass  enhancement  is  characterized  by  its  spatial
distribution  and  internal  enhancement  patterns.  A  major
element  in  the  description  is  the  symmetrical  or  asymmet-
rical  character  of  the  NME  and  the  detection  of  associated
signs.
Descriptive  criteria
Distribution:  focal,  linear,  segmental,  regional,  multiple
regions,  diffuse.
Internal  enhancement  patterns:  homogeneous,  hetero-
geneous,  stippled,  clumped,  reticular  (dendritic).Symmetry:  the  symmetrical  character  of  a  non-mass
enhancement  is  suspected  except  in  the  event  of
contra-lateral  radiotherapy  (ﬁbrosis  and  post-therapeutic
hypovascularization).
p
o
1
cAssociated  features:  nipple  abnormalities  (retraction,
nvasion),  spontaneous  high  T1  signal  of  ducts,  focal  or  dif-
use  thickening  of  the  skin,  skin  invasion,  edema,  lymph
ode  enlargement,  pectoral  invasion,  hematoma,  cysts.
In  summary,  the  reliability  and  reproducibility  of  the  var-
ous  descriptive  criteria  of  NME  make  the  inclusion  of  the
onventional  report  an  important  component  in  the  diag-
ostic  work-up.  The  diagnostic  tree  in  Fig.  2  summarizes
he  diagnostic  reasoning  for  a  non-mass  enhancement  [9].
ocus
eﬁnition
omogeneous  enhancement  of  less  than  5  mm  that  is  not  a
ass.
haracterization  and  descriptive  criteria
hree  important  notions  to  consider:  single  or  multiple,  the
ype  of  enhancement  curve,  and  the  notion  of  a  high  risk  for
reast  or  ovarian  cancer.
ummary
ultiple  and  bilateral  foci  are  classiﬁed  as  ACR  2  (even  in
igh-risk  cases).  The  discovery  of  an  isolated  focus  should
rompt  an  ultrasound  examination  to  eliminate  the  presence
f  a  mass.  If  no  mass  is  found  on  ultrasound  and  with  a  type
 or  2  curve,  the  enhancement  is  classiﬁed  as  ACR  3.  If  the
urve  is  type  3,  an  MRI  guided  biopsy  is  an  option.
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The  authors  declare  that  they  have  no  conﬂicts  of  interestigure 2. Report of a non-mass enhancement [9] in a patient wit
onclusion
he  various  essential  elements  that  should  be  included  in
n  imaging  report  are  presented  in  the  appendix.  A  good
nterpretation  should  include  the  various  imaging  techniques
nd  summarize  the  diagnostic  strategy  for  the  clinician.
TAKE-HOME  MESSAGES
Good  interpretation  in  imaging  should:
• respect  the  descriptive  guidelines  of  the  BI-RADS
terminology;
• include  the  various  imaging  techniques;
• summarize  the  diagnostic  strategy  for  the  clinician;
ase report
uestions.  Which  elements  should  be  included  in  a  mammography
report?
A.  Tumor  size
B.  The  presence  of  an  opacity
cw risk of breast cancer.
C.  The  existence  of  an  asymmetrical  density
D.  Breast  composition
E.  The  mean  glandular  dose
.  Which  elements  should  be  included  in  a breast  MRI
report?
A.  Physiological  glandular  enhancement
B.  Breast  density
C.  The  number  of  the  slice  on  which  an  anomaly  is
detected
D.  The  ACR  classiﬁcation
E.  The  diagnostic  strategy  for  each  of  the  abnormalities
detected
nswers
.  Answers:  A,  C,  D,  E
.  Answers:  A,  B,  C,  D,  Eoncerning  this  article.
765Standardized  diagnosis  and  reporting  of  breast  cancer  
Appendix A.
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